NORWICH – Norwich Pharmaceuticals, Inc. (Norwich), a leader in full-service contract development and manufacturing, today announced the formation of Norwich Clinical Services to provide clinical testing capabilities that will further expand the company’s third party services. Norwich Clinical Services will offer a complete range of clinical research capabilities including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services.  

“The introduction of Norwich Clinical Services underscores our strategic focus to provide customers with a comprehensive solution for all stages of product life cycle management,” said Doug Drysdale, chief executive officer of Alvogen, a company that includes Norwich Pharmaceuticals and Norwich Clinical Services. “We have assembled the highest level of professional expertise to ensure Norwich Clinical Services matches our tradition of unparalleled quality standards and delivers contract pharmaceutical services with everyday excellence.”

Dr. Saral Thangam, MD, PhD, managing director of Norwich Clinical Services, will lead an experienced team of professionals who each have at least 15 years experience in clinical research and life sciences. Dr. Thangam completed her medical training with an Internal Medicine specialization at Christian Medical College, Vellore, and her PhD in physiology was earned at St. John’s Medical College, Bangalore. Prior to joining Norwich, Dr. Thangam was the managing director of Lotus Labs.